{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:09:09Z","timestamp":1778152149801,"version":"3.51.4"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Ceftazidime\u2013avibactam was approved by the US Food and Drug Administration in 2015 to treat complicated intra-abdominal and urinary tract infections in adults and is under clinical development for treating pediatric patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Among 53,381 Gram-negative organisms (1 per patient) collected in 2011\u20132015, 8461 (15.9%) were from pediatric (\u226417 years old) patients. The isolates were collected from 82 US medical centers and susceptibility tested against ceftazidime\u2013avibactam (avibactam at fixed 4 \u03bcg\/mL) and comparators by reference broth microdilution methods. Susceptibility results were stratified by patient age: \u22641 (3671 isolates); 2\u20135 (1900); 6\u201312 (1644) and 13\u201317 years old (1246). Enterobacteriaceae with an extended-spectrum \u03b2-lactamase (ESBL) screening-positive phenotype were evaluated by microarray-based assay for genes encoding ESBLs, KPC, NDM and transferable AmpC enzymes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Ceftazidime\u2013avibactam inhibited &gt;99.9% of all Enterobacteriaceae at the \u22648 \u03bcg\/mL susceptible break point and was highly active against ESBL screening\u2013positive phenotype<jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic>and<jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic>. Overall, 83.6% of ESBL screening\u2013positive phenotype<jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>were susceptible to meropenem. Only 1 of 4724 Enterobacteriaceae (0.02%) isolates was nonsusceptible to ceftazidime\u2013avibactam, an<jats:italic toggle=\"yes\">Enterobacter aerogenes<\/jats:italic>with a ceftazidime\u2013avibactam minimum inhibitory concentration (MIC) value of 16 \u03bcg\/mL and negative results for all \u03b2-lactamase tested. Ceftazidime\u2013avibactam was very active against<jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic>(MIC<jats:sub>50\/90<\/jats:sub>, 1\/4 \u03bcg\/mL; 99.1% susceptible), including isolates nonsusceptible to meropenem (94.0% susceptible to ceftazidime\u2013avibactam) or piperacillin\u2013tazobactam (91.7% susceptible) or ceftazidime (89.6% susceptible). Ceftazidime\u2013avibactam activity against<jats:italic toggle=\"yes\">P. aeruginosa<\/jats:italic>did not vary substantially among age groups (98.8%\u201399.3% susceptible) or year of isolation (98.5%\u2013100.0% susceptible).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Ceftazidime\u2013avibactam was very active against a large collection of Gram-negative bacilli isolated from pediatric patients, including<jats:italic toggle=\"yes\">P. aeruginosa<\/jats:italic>and Enterobacteriaceae with an ESBL screening\u2013positive phenotype and resistant to carbapenems.<\/jats:p><\/jats:sec>","DOI":"10.1097\/inf.0000000000001859","type":"journal-article","created":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T22:22:08Z","timestamp":1512512528000},"page":"549-554","source":"Crossref","is-referenced-by-count":18,"title":["Ceftazidime\u2013Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients"],"prefix":"10.1097","volume":"37","author":[{"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[{"name":"From the JMI Laboratories, North Liberty, Iowa."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Huband","sequence":"additional","affiliation":[{"name":"From the JMI Laboratories, North Liberty, Iowa."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard R.","family":"Duncan","sequence":"additional","affiliation":[{"name":"From the JMI Laboratories, North Liberty, Iowa."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"From the JMI Laboratories, North Liberty, Iowa."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/cid\/ciu069","article-title":"Treatment of multidrug-resistant Gram-negative infections in children.","volume":"58","author":"Hsu","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijantimicag.2014.01.007","article-title":"Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012.","volume":"43","author":"Sader","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/joim.12342","article-title":"Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control.","volume":"277","author":"T\u00e4ngd\u00e9n","year":"2015","journal-title":"J Intern Med"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"e02252","DOI":"10.1128\/AAC.02252-16","article-title":"Antimicrobial susceptibility of Pseudomonas aeruginosa: results from four years (2012\u20132015) of the International Network for Optimal Resistance Monitoring (INFORM) Program in the United States.","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1111\/j.1469-0691.2011.03514.x","article-title":"Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment.","volume":"17","author":"Zarkotou","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-avibactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination.","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ijantimicag.2015.08.011","article-title":"A resurgence of \u03b2-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.","volume":"46","author":"Bush","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"6252","DOI":"10.1128\/AAC.00862-16","article-title":"Phase I study sssessing the pharmacokinetic profile, safety, and tolerability of a single dose of ceftazidime-avibactam in hospitalized pediatric patients.","volume":"60","author":"Bradley","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1128\/AAC.00540-16","article-title":"Changes in the frequencies of \u03b2-lactamase genes among Enterobacteriaceae isolates in U.S. hospitals, 2012 to 2014: activity of ceftazidime-avibactam tested against \u03b2-lactamase-producing isolates.","volume":"60","author":"Castanheira","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1093\/cid\/civ020","article-title":"Extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae in children: old foe, emerging threat.","volume":"60","author":"Lukac","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/MOP.0000000000000182","article-title":"The contribution of extended-spectrum \u03b2-lactamases to multidrug-resistant infections in children.","volume":"27","author":"Murray","year":"2015","journal-title":"Curr Opin Pediatr"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","article-title":"Updated functional classification of beta-lactamases.","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R18-20230912","first-page":"165","article-title":"Vital signs: carbapenem-resistant Enterobacteriaceae.","volume":"62","author":"Jacob","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/cid\/cir202","article-title":"Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention.","volume":"53","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/jpids\/pit049","article-title":"Microbiological and genetic characterization of carbapenem-resistant Klebsiella pneumoniae isolated from pediatric patients.","volume":"3","author":"Dara","year":"2014","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/INF.0000000000000471","article-title":"Pediatric carbapenem-resistant Enterobacteriaceae in Los Angeles, California, a high-prevalence region in the United States.","volume":"34","author":"Pannaraj","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/cid\/cis543","article-title":"Carbapenem-resistant enterobacteriaceae: an emerging problem in children.","volume":"55","author":"Logan","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R23-20230912","first-page":"352","article-title":"Multidrug- and carbapenem-resistant Pseudomonas aeruginosa in children, United States, 1999\u20132012.","volume":"6","author":"Logan","year":"2017","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dkw239","article-title":"Spotlight on ceftazidime\/avibactam: a new option for MDR Gram-negative infections.","volume":"71","author":"Falcone","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"R25-20230912","doi-asserted-by":"crossref","first-page":"pii: e0244716","DOI":"10.1128\/AAC.02447-16","article-title":"Molecular beta-lactamase characterization of aerobic Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials for complicated intra-abdominal infections: Efficacies analyzed against susceptible and resistant subsets.","volume":"61","author":"Mendes","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R26-20230912","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1128\/AAC.00655-15","article-title":"Successful treatment of carbapenemase-producing pandrug-resistant Klebsiella pneumoniae bacteremia.","volume":"59","author":"Camargo","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijid.2017.03.021","article-title":"Clinical efficacy of ceftazidime\/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients.","volume":"59","author":"Caston","year":"2017","journal-title":"Int J Infect Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201806000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T03:55:12Z","timestamp":1751082912000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201806000-00011"}},"subtitle":["Results From the INFORM Surveillance Program (United States, 2011\u20132015)"],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001859","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}